Elafibranor is primarily used in the treatment of non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease. It works by targeting metabolic pathways involved in inflammation, lipid metabolism, and insulin sensitivity through dual activation of PPARα and PPARδ receptors. This helps reduce liver fat accumulation, inflammation, and fibrosis. Elafibranor has shown potential in clinical trials to improve liver histology without worsening fibrosis, making it a promising candidate for halting NASH progression. It is also being investigated for its benefits in patients with type 2 diabetes and dyslipidemia due to its metabolic effects.